🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Olympus Corporation (TYO:7733)
Japan flag Japan · Delayed Price · Currency is JPY
1,798.00
+6.00 (0.33%)
Nov 18, 2026, 3:30 PM JST
← View all transcripts

Earnings Call: Q2 2027

Nov 10, 2026

Summary

FY guidance rose for revenue, operating margin and EPS, with confidence centered on the range midpoint. North American demand remains positive; China faces GI-ET pricing pressure, while FDA remediation focuses on sustained, consistent quality execution.

Speaker 1

Now we would like to start the Q&A session. My first question is about business environment, specifically North America. What is your outlook in North America? In the first quarter, GI Endoscopy did very well, but basically 3% increase, and maybe this is slowing down. Can you achieve the second half target? The growth seems to be stagnating or slowing down. What is the factor behind this? That's my first question.

Bob White
President and CEO, Olympus

Yeah, thank you for the question. When we look at North America, when we look at the first half performance, it's right on where we thought it would be. We saw very good growth in GI ET, urology, and respiratory in North America. In the core GI business in North America, the Q2 results really were the result of some deals that delayed closing in the quarter, and we expect those to close in the second half of the year. We actually do not see North America slowing down. We like where we're positioned in North America.

Speaker 1

Understood. My follow-up, my second question is about FDA response. You have already explained this in your presentation, but effectiveness and also the sustainability of the remediation has to be demonstrated, proven. What kind of impact will this have on finance and accounting in terms of cost, headcount increase, or how long it would take? Based on the most recent letter from FDA, does it impact your outlook on the cost on your financials?

Bob White
President and CEO, Olympus

Yeah, thank you for the question, and let me reiterate that we certainly take this very seriously. The Warning Letter really classifies the inspections that took place last fall. Since January of last year, when we saw the observations, we accelerated our efforts in a number of the areas that I talked about. As it relates to the cost, we believe that we have that within the budget as we look to continue to ensure we finish what we started here. But also, if we need to make additional trade-offs within it, we will, meaning that we will deliver our revenue and operating margin expansion while ensuring that we deliver on our quality system remediation.

Yeah, all good.

Speaker 1

Understood. Thank you.

Speaker 3

I want to ask you about your guidance on slide 28, right? Slightly more detailed here. So it looks like, it appears to me that excluding the tariff refund, the operating profit and net income guidance actually were revised down by about 3% and 8% respectively, right? Am I correct in my understanding? If so, may I ask why that is the case?

Bob White
President and CEO, Olympus

No, I actually don't believe you're correct. Our guidance was raised on revenue, operating margin, and earnings per share.

Speaker 3

Okay. Maybe we can take this offline. I am just comparing that to your first quarter results, where you have a similar slide, right? It looks like the absolute number of operating profit and net income appears to have declined, excluding the tariff refund benefit.

Michael Parenti
CFO, Olympus

We will have to take that offline. To be truthful, I mean, that is not the situation. I mean, in August when we came out, we had a 14.9 at a managerial basis operating margin profit. What we are showing now is something much higher than that. I just think we need to make sure that we are connected on the numbers.

Speaker 3

Yeah, I have a question on, follow-up question on slide number 11. That is GI Endoscopy. It declined 3%, right, in constant currency in the second quarter. You commented it is due to North America declined due to a one-time prior year impact and extended deal timeline. Can you explain this?

Bob White
President and CEO, Olympus

Yeah. In fact, I will have Keith weigh in here. But yeah, those were really the two factors when we looked at the performance in the quarter, was we had royalty revenue from Swan in the prior year, and then we had a number of capital deals. But Keith, why don't you characterize kind of how we are seeing the market in North America for GI?

Keith Boettiger
Executive Officer and Head of Gastrointestinal Solutions Division, Olympus

Yeah, look, I mean, we still see underlying demand in North America as positive and good, and we still see strong demand for EDOF scopes. As Bob said, and as you repeated, I mean, we saw some deals push off out of Q2 into the second half of the year, and that one-time licensing payment. But right now, we have confidence in the number going into the second half of the year and into our pipeline and into the team's ability to execute commercially as we close out the next two quarters.

Bob White
President and CEO, Olympus

Building on Keith's point, one of the things we look at is the strength of the order book in all the regions and in North America. We like the strength of the order book. Certainly, timing is important that these deals land when we expect them to land, but we know that we've got that, and the second half looks good.

Speaker 3

Yeah, thank you very much.

Speaker 6

Thank you, Tony. With regard to the guidance, our team will get in touch with you offline for follow-up. Adjusted OPM and EPS, we have increased the lower limit.

Speaker 7

My question is about the FDA Warning Letter you received in October. Yes, I hear your explanation, Bob, but unfortunately, Japanese analysts or investors are not very familiar with Warning Letter issue, unfortunately. We still have a bit of a concern on the issue. Because basically, I think if I read the Warning Letter from FDA, all talk about CAPA things. I believe that the FDA really want to make sure kind of the metric effectiveness, as far as I understand. You have been working on this issue for many years, but still this issue, it pops up. I totally understand you give us a lot of explanation, but could you give us additional explanation how to tackle with the issues currently FDA is pointing out, especially about CAPA, metrics effectiveness, or all those issues?

I know that you are having new people to fix the issue, but what is going to change from the past to now or in the future? That kind of FDA-related issue, if you could follow up, that would be helpful. Thank you very much.

Bob White
President and CEO, Olympus

Yeah, thank you very much for the question. I will have Brian Barry , our relatively new Head of Quality, jump in for a minute, but let me just get started. Your question is, why should we believe it is different this time? I would offer you that is because since January, we have been doing things differently. We have invested in leaders across our functions. We keep investing them to do the job right. Before, we closed actions, I think when the work was done. Now, we close them on evidence that the fix lasts and this learning carries across to every site.

Brian, I think it would be helpful, do you offer your observations here?

Brian Barry
Head of Quality, Olympus

Yeah. Thanks, Bob, and thank you for the question. In terms of what I have been seeing so far, the Olympus quality system is well-developed and, in general, has the right content. But the procedures governing CAPA and complaint handling, MDR, process validation, et cetera, need to be executed more evenly across our facilities. When I think about it, we need to be able to demonstrate that we are doing things the same way at every site every single day. We have to prove with evidence how we comply with quality system requirements. To your question, an important part of that is being able to demonstrate that corrective actions, when necessary, actually fix the problem, and as Bob said, are sustainable on the long run. That is really what the Warning Letter is telling us.

As Bob said, we're accelerating a number of things using industry experts to help guide and independently verify the next phase of our transformation. First, corrective actions, as Bob said, will be closed on evidence that they were effective and sustainable, just not on work being finished. Two, we're investing in reliability engineering and advanced signal detection techniques to help us analyze service and customer complaint data in a more sophisticated and timely manner. Last but not least, when it comes to process validation, we're making that a core skill at every single manufacturing site to help drive consistent product quality.

As Bob said, we still have work to do, but we'll judge ourselves on our future inspection results as a key indicator of the effectiveness of our work going forward, and we'll continue to use our strategic pillars of innovation-driven growth, simplicity, and accountability to guide our work.

Bob White
President and CEO, Olympus

Thanks, Brian.

Speaker 7

Thank you very much. I've got quick two follow-up questions on your answers. One is, what kind of timeframe you're expecting to fix this metric effectiveness or CAPA issues? 12 months or six months? If you could give us the guidance, that would be helpful. Also, the receipt of the Warning Letter would affect your plan for the strategic option for the surgical business? That's two follow-up. Thank you very much.

Bob White
President and CEO, Olympus

Yeah. Brian, I will let you address the first part of that question in a minute relative to timeframe and how we think about both. Our work is underway now, but of course, Brian will talk about when the FDA could return at their discretion. The second part of your question was, does our quality remediation work affect the strategic review of the surgical business? To be clear, the strategic review of the surgical business is still ongoing. I do not have anything to report at this moment. As I said, when I do, I certainly will disclose that to you. But make no mistake, quality, patient safety are at the top of our list, regardless of which business unit it is, and we will work on remediating that across.

Certainly, as we talked about and as Michael mentioned, we saw some early lifts of some ship-holds, which meant that we had remediated some products and got those back into the marketplace. Hopefully that is helpful context. Then Brian, if you want to speak, specifically the question about, I think, was the CAPA process and how we provide objective evidence that CAPAs are effective.

Brian Barry
Head of Quality, Olympus

Yeah. Thanks, Bob, and thanks for the question. We are currently in the process of improving our CAPA process. The focus there is really twofold. First of all, using Lean Six Sigma techniques, we are improving the efficiency and repeatability of our baseline process. Concurrent with that, we are also reviewing our overarching policy for CAPA and making sure that every site, as I said before, is implementing the requirements of that procedure consistently. Really what we are working on is making sure that every site is being driven to inspection readiness each and every day.

We are going to continue to share progress with FDA, but the timing of future inspections is really up to them. At this point, we do not have any dates for future inspections set.

Bob White
President and CEO, Olympus

Thanks, Brian.

Speaker 9

I have two questions actually on China. My first question is that in the first half, Chinese business actuals, is it better or worse than the plan and budget? That is my first question. Second quarter, the second half, are you going to improve from the first half? If there is any changes, is it reflected in the guidance?

Bob White
President and CEO, Olympus

Yes. Thank you for your questions. I will answer both of them. China is moving as expected, which is the decline narrowing each quarter, and Q2 was in line with our internal expectations. Certainly, we have spoken about in the past the policy shifts, the national VBP, our efforts on localization, but we expect gradual improvement, as we talked about, for the second half, and our guidance reflects accurately what our performance outlook is in China.

Speaker 9

Thank you very much. I have a follow-up question for next year, for FY 2028, actually March 2028, for Chinese VBP, what is your outlook? Sometimes in endoscope area, there might be a unit price decline, price reduction is rumors and concerns we hear, and there are some concerns. From your point of view, for next fiscal year, what is your outlook of Chinese business and what is the impact of VBP?

Bob White
President and CEO, Olympus

Yes. Thank you very much for the question. You are correct that we expect a national VBP broader than the regional programs we have seen with GI-ET particularly. As we do our FY 2028 planning, we have that factored in based on what we know today. Importantly, while we certainly will see some pricing pressure on GI-ET in China, the underlying procedure demand is strong, so this is primarily a pricing challenge, and we are responding by shifting towards more differentiated products, developing different products for China, improving our commercial and cost structure. China remains an important long-term market for Olympus, and our focus is really on adapting the business to compete successfully in this new environment.

Speaker 9

Let me confirm once again. ET , you said EndoTherapy. Is that the EndoTherapy? How about endoscope per se or EVIS X1? That unit price is not going to be a concern? Do you think that the price is going to solid?

Bob White
President and CEO, Olympus

Yeah, no, we actually, to be clear in my answer, we see the pressure on GI-ET from the national VBP. We do not see further price erosion than what we've planned already in the other categories.

Speaker 9

Thank you very much. That's all my questions.

Speaker 10

I guess I'll ask Brian Barry about how you see the quality system at Olympus. I think you described it a little bit, but I think it's been last three months you've probably been able to get to know more about Olympus's quality system vis-à-vis your former employer. You said that execution is the problem. The long Warning Letter seemed to suggest that the former management only put in a global CAPA system, but wasn't successful in changing the people and culture. It would seem like a long haul changing people and culture, but my question is this: How do you see the quality culture at Olympus? Are there problems within the culture, and how will you change the quality culture? That's my first question.

Brian Barry
Head of Quality, Olympus

Yeah, thank you for that question. There is certainly a cultural element. My conclusion is that we simply were not clear enough on the roles between the sites and the global functions. We are working through that right now. We also didn't do enough oversight, as Bob alluded to before. Oversight is an important part of the verification process, and we need to make sure that we generate evidence of work completion and sustainability. That's fixable. We are doing it. Relative to comparison with other places I've worked, again, I think the SOPs themselves, the procedures themselves, are largely fine. We just need to work on that execution piece.

Yes, that will drive cultural change, and we are committed to bringing in outside experts as well as leveraging our internal experts at a greater degree to make sure that the work is implemented consistently across all facilities and any improvements that we make are sustainable. Again, that's consistent with what the Warning Letter tells us.

Speaker 10

Thank you. My final question is really for Bob. Most Japanese analysts are not aware of what happens when the same facility or company receives repeated Warning Letters. The worst-case scenario is called a consent decree. It would seem that at least Hinode has received two Warning Letters. Can you give us any assurance that all of this will not proceed to a consent decree? If it does, can Olympus still maintain the margin improvement target of 100 bps or better? That's my final question.

Bob White
President and CEO, Olympus

Thank you, Katani-san. Certainly, I won't speculate on any regulatory outcomes. We've not been advised of any FDA action beyond what we've disclosed. As Brian and I have both talked about, the best protection against escalation is evidence that our fixes work, and that's where our effort goes. We've submitted a very comprehensive response to the Warning Letter, and again, I would offer to you, we've accelerated action since January when we learned of the observations. It will take some time for the FDA to review our evidence and our responses. The FDA has asked for evidence of completion and sustainability, and that's what we'll do, and that's where our focus is. I think you're right to point it out, but I don't believe that if we do our job, that's where this ends up.

Speaker 10

About the margin expansion target if you go into a consent decree?

Bob White
President and CEO, Olympus

Look, I think our plan around revenue growth and margin expansion is fine as it is, and I am standing behind it. Certainly, we could develop a number of scenarios that would be disruptive to our plan, but I do not believe there is anything I see now that is disruptive to our revenue and operating margin plan of the nature you described.

Speaker 10

Okay, thank you.

Speaker 11

I have two. The one is you expressed about the confidence in achieving the guidance. However, since you guys given the range, could you clarify whether the confidence is primarily around achieving the lower end or whether you are always confident in reaching the upper end of the range? Thank you. This is my first question.

Bob White
President and CEO, Olympus

Go ahead, Michael, you want to take that?

Michael Parenti
CFO, Olympus

Sure. Hey, thanks for the question. Look, when we evaluated our guide for second quarter for the full year, we had to evaluate where we are midway through the year. Like we talked about, we feel really comfortable with the performance through the first half of the year. When we think about some of the tailwinds that we have as we exit the first half and get into the second half, we feel very good about the catalyst for our GI business. We talked about the ship-holds returning earlier than expected. Then, of course, in the SG&A line, you'll see that in some of the reporting, we've seen some of the efforts from the OPM change working through the P&L.

We feel very good about raising the bottom. Again, I think for us, we want to make sure that there's space in the range in case something were to take place that we weren't expecting. But I think we're comfortable in the middle part of that range for sure.

Bob White
President and CEO, Olympus

Yep, that's correct.

Speaker 11

What else risk you are consider about in the half paths?

Bob White
President and CEO, Olympus

Look, from my perspective, we have to execute our plan, which means we need to get products to the marketplace. We need to drive commercial execution. We absolutely will focus on our quality system remediation. We're focused on the things that are in our control, and I think the previous questions also talked about how we're thinking about China and the dynamics in the market there. Importantly, I would offer you that ship-holds and recalls, those are temporal, but the underlying demand for endoscopy-enabled care is not. We're in good markets with good businesses, and that's our focus.

Speaker 11

Okay, thank you. My second question is, since you have already been working on the quality improvement for several years, and following this, like the import alert issued in December, could you clarify what area, what field you now see as remain challenge in meeting at these expectations, and which things you believe have already been adequately addressed?

Bob White
President and CEO, Olympus

Yeah. Thank you for the question. As Brian and I said, when we think about the work that was done with Project Elevate, this was putting global systems in place for things like complaint handling, MDR, which means adverse event reporting, process validation. Those were important foundational elements. Where we've been accelerating our efforts is to make sure that we execute consistently across all of our sites, and we have to do a better job of that. Where we fix something in one site, make sure that that is fixed horizontally in other sites. What the agency has asked for is show us evidence that's sustainable. Our focus now is really on showing that sustainable evidence. Two, we are investing in reliability engineering and advanced signal detection to analyze our customer complaints more vigorously.

Then three, as Brian mentioned, we are making sure that process validation, monitoring, and control become a core skill at every manufacturing site. I would say that is the work that we are on. The reason I am very pragmatic in our approach here is we have got a foundation, we need to improve our execution, and we need to execute consistently across our sites. That is what the FDA wants. They want sustained evidence that we detect early and escalate our complaint data, and also that we have good control of non-conforming suppliers, and that we fix issues horizontally. As Brian mentioned, we are moving into this as the top priority to accelerate the work that we really began in January as the results of the inspection became known to us.

Of course, we did not know how the agency was going to classify the inspections until the October Warning Letter, but that did not stop us. We got to work right away in January.

Speaker 11

Thank you. Totally understood. Thank you. That is all.

Speaker 12

Congratulations on a strong commercial performance. Bob, could you talk about the division-led operating model that you have implemented, and how is that contributing to the commercial execution, please?

Bob White
President and CEO, Olympus

Thanks, Steven. When we announced our revised strategy last November of innovation-driven growth, simplicity, and accountability, we believed in this middle pillar of simplicity that a pivot to a division-led operating model would streamline decision-making. The other thing it did was it identified redundancies. When we talked about our execution of those position optimizations, and we have delivered on that commitment of the JPY 24 billion run rate savings, this has really enabled that. This is just the first step. What we like about the division operating model is it continues to identify ways that we can drive efficiency and simplicity across Olympus. We are not resting, and we are going to continue to focus on that.

Speaker 12

Thanks very much.